Chrissy Metz Highlights Inflammation Relief and Mental Clarity as Key GLP-1 Benefits

Key points

• Metz, 46, reported that her inflammation has 'really minimized' since starting the medication, which aided her in performing eight shows a week in the Broadway production & Juliet.
• She described the mental capacity to stop obsessing over food as 'super, super helpful,' noting that the medication helped quiet 'food noise.'
• Metz acknowledged her initial skepticism but was convinced after a friend provided thorough research on the drug's benefits beyond weight loss.
• The Daily Beast reported that Metz has lost 63 pounds since beginning the treatment, while E! Online noted she had lost 60 pounds in previous reports.
• Metz stated she hopes her openness will help others feel less afraid of public judgment regarding their health choices.

Background

Metz first disclosed her use of GLP-1 medication in August 2026, explaining that she had been 'very skeptical' due to her diligence regarding how substances affect the body. She noted that she had struggled with weight since childhood and felt shame associated with larger bodies. Recent studies presented in October 2026 have linked GLP-1 use to higher rates of hair and nail loss, though experts suggest rapid weight loss may be the primary cause rather than the drug itself. Other celebrities, including Serena Williams and Oprah Winfrey, have also publicly discussed their use of similar medications for weight management and health improvements.

How outlets are covering it

E! Online and KOMO emphasized Metz's physical stamina and reduced inflammation, linking these benefits to her ability to sustain a demanding Broadway schedule. The Daily Beast focused on the specific weight loss figure of 63 pounds and the mental health aspect of reduced food obsession. While all sources agree on the positive outcomes, E! Online highlighted Metz's desire to normalize the conversation to reduce public judgment, whereas The Daily Beast contextualized the 'food noise' reduction within the broader mechanism of appetite-suppressing drugs like Wegovy and Zepbound.

Why it matters

Metz's account provides a high-profile example of GLP-1 medications being used for benefits beyond weight loss, such as managing perimenopausal symptoms and improving mental clarity. Her public endorsement may influence public perception of these drugs, potentially reducing the stigma associated with their use among individuals with metabolic or inflammatory conditions.

What to watch

Metz has expressed hope that her experience will 'enlighten people to an option that might be right for them.' As more celebrities and public figures share their experiences, the conversation around GLP-1 medications is likely to expand beyond weight loss to include broader health and mental well-being outcomes. Continued research into the long-term effects of these medications, including potential side effects like hair loss, will also be important for public health discussions.